Albumin is given in cirrhosis during several specific complications: large-volume paracentesis, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome, and acute kidney injury. Each situation has its own dosing protocol and timing. In some cases, long-term weekly albumin infusions may also improve survival in patients with decompensated cirrhosis and persistent ascites.
During Large-Volume Paracentesis
When more than 5 liters of fluid are drained from the abdomen, albumin prevents a dangerous drop in circulating blood volume known as post-paracentesis circulatory dysfunction, or PPCD. The American Association for the Study of Liver Diseases (AASLD) recommends 6 to 8 grams of albumin per liter of fluid removed. So if 8 liters are drained, you’d receive roughly 48 to 64 grams of albumin intravenously.
Without albumin, about one in three patients develops PPCD after large drainage. With albumin, that rate drops to roughly 11%. The difference matters because PPCD can trigger kidney failure and worsen the overall trajectory of liver disease.
If less than 5 liters are removed, albumin generally isn’t necessary. A randomized trial comparing albumin to saline found virtually no difference in PPCD rates when under 6 liters were drained (about 6% in both groups). For smaller taps, saline alone appears sufficient.
During Spontaneous Bacterial Peritonitis
SBP is a life-threatening infection of the abdominal fluid that occurs in cirrhosis patients with ascites. Albumin is given alongside antibiotics, not as a replacement for them, because SBP triggers intense inflammation that pulls fluid out of circulation and damages the kidneys. Albumin helps maintain blood volume and protect kidney function during this critical window.
The standard protocol, established in a landmark 1999 trial of 126 patients, is 1.5 grams per kilogram of body weight within 6 hours of diagnosis, followed by 1.0 gram per kilogram on day 3. For a 70-kilogram person, that works out to about 105 grams on day one and 70 grams on day three.
This regimen is most clearly beneficial in higher-risk patients, specifically those with elevated bilirubin or creatinine levels at the time of diagnosis. These markers signal that the liver and kidneys are already under significant stress, making circulatory collapse more likely without albumin support. Some researchers are studying whether lower doses might work just as well, but the standard protocol remains the current recommendation.
In Hepatorenal Syndrome
Hepatorenal syndrome (HRS) is a form of kidney failure caused by severe circulatory dysfunction in advanced liver disease. The kidneys themselves aren’t structurally damaged, but they stop receiving adequate blood flow. Treatment combines vasoconstrictors (medications that tighten blood vessels to redirect blood toward the kidneys) with albumin to expand circulating volume.
Both the International Ascites Club and the AASLD recommend albumin as part of first-line therapy for the most severe form of HRS. The typical approach is 1 gram per kilogram on the first day, capped at 100 grams, followed by 20 to 40 grams daily for the duration of vasoconstrictor treatment. The goal is to restore enough effective blood volume that the kidneys begin functioning again, ideally bridging the patient to a liver transplant.
For Acute Kidney Injury
When a patient with cirrhosis develops acute kidney injury (AKI), albumin is used as a diagnostic and therapeutic tool. The idea is to give albumin to expand blood volume and see whether kidney function improves. If it does, the AKI was likely caused by dehydration, over-diuresis, or another reversible cause. If it doesn’t, clinicians suspect hepatorenal syndrome and escalate treatment.
EASL and AASLD guidelines recommend albumin at 1 gram per kilogram per day for 48 hours in patients with AKI and suspected volume depletion or early hepatorenal syndrome. A recent consensus meeting proposed shortening this to 24 hours, though this change is based on expert opinion rather than trial data. In practice, the 48-hour protocol remains widely used, particularly when the cause of kidney injury is unclear.
Long-Term Weekly Infusions
A newer and more debated use is ongoing outpatient albumin therapy for patients with decompensated cirrhosis and recurrent ascites. The ANSWER trial, published in The Lancet, randomized patients to either standard care or standard care plus regular albumin infusions: 40 grams twice weekly for two weeks, then 40 grams once weekly for up to 18 months.
The results were notable. Eighteen-month survival was 77% in the albumin group compared to 66% with standard care alone, a 38% reduction in the risk of death. Patients receiving albumin also had fewer complications, including less ascites, fewer infections, and fewer hospitalizations. This approach treats albumin not just as a rescue therapy during acute events, but as ongoing support for the failing circulation that drives most complications of advanced liver disease.
Long-term albumin therapy isn’t yet universally adopted, and it requires regular clinic visits for infusions. But for patients with refractory ascites who are frequently hospitalized, it represents a meaningful option.
Risks of Albumin Infusion
Albumin is not without risks in cirrhosis patients. The primary concern is pulmonary edema, a dangerous buildup of fluid in the lungs. Cirrhotic patients already have abnormal fluid distribution throughout the body, and pushing large volumes of albumin in a short time can overwhelm the heart’s ability to handle the increased blood volume.
An international position statement on albumin use in cirrhosis recommends stopping infusions if serum albumin levels rise above 45 grams per liter, and immediately discontinuing albumin if signs of pulmonary edema develop. Central venous pressure monitoring can help prevent overload when available. The risk is highest during high-dose, rapid infusions, particularly when albumin is combined with vasoconstrictors for hepatorenal syndrome. A more cautious “restrictive” infusion strategy may reduce this risk in certain situations, though SBP remains one scenario where the full standard dose is given regardless.